Literature DB >> 20711283

Cutaneous malignant melanoma associated with papillary thyroid cancer.

Chi Yeon Kim1, Seung Hun Lee, Chee Won Oh.   

Abstract

As the survival from cutaneous malignant melanoma and its clinical concerns have been steadily increasing, the possibility has been raised of an increased risk of second primary cancers in the patients with malignant melanoma. Especially, recent studies have identified an association between cutaneous malignant melanoma and thyroid carcinoma. We here report on a case of cutaneous malignant melanoma that developed in a 61-year-old female patient who had hypothyroidism caused by papillary thyroid carcinoma. We suggest that the individuals who have cutaneous malignant melanoma may be predisposed to other primary cancers and especially thyroid carcinoma. Continuous monitoring of the thyroid function in melanoma patients is required because hypothyroidism can worsen due to malignant melanoma and this is probably associated with thyroid carcinoma.

Entities:  

Keywords:  Hypothyroidism; Melanoma; Papillary thyroid carcinoma

Year:  2010        PMID: 20711283      PMCID: PMC2917700          DOI: 10.5021/ad.2010.22.3.370

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  6 in total

1.  High prevalence of hypothyroidism in male patients with cutaneous melanoma.

Authors:  Monica Shah; Ida F Orengo; Ted Rosen
Journal:  Dermatol Online J       Date:  2006-02-28

2.  Elevation of thyroid cancer risk among cutaneous melanoma survivors.

Authors:  William Goggins; Gilbert H Daniels; Hensin Tsao
Journal:  Int J Cancer       Date:  2006-01-01       Impact factor: 7.396

3.  Malignant melanoma and coexisting malignant neoplasms.

Authors:  D G Fraser; J G Bull; J E Dunphy
Journal:  Am J Surg       Date:  1971-08       Impact factor: 2.565

4.  Human melanoma cells express functional receptors for thyroid-stimulating hormone.

Authors:  Julie A Ellerhorst; Aresu Sendi-Naderi; Marilyn K Johnson; Carolyn P Cooke; Shyam M Dang; A Hafeez Diwan
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

5.  Expression of thyrotropin-releasing hormone by human melanoma and nevi.

Authors:  Julie A Ellerhorst; Aresu A Naderi; Marilyn K Johnson; Pauline Pelletier; Victor G Prieto; A Hafeez Diwan; Marcella M Johnson; Debra C Gunn; Sandra Yekell; Elizabeth A Grimm
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

6.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

  6 in total
  5 in total

1.  Melanoma and Thyroid Carcinoma: Our Current Understanding.

Authors:  Danielle R Lazzara; Sonya G Zarkhin; Samuel N Rubenstein; Brad P Glick
Journal:  J Clin Aesthet Dermatol       Date:  2019-09-01

2.  Malignant melanoma and papillary thyroid carcinoma that were diagnosed concurrently and treated simultaneously: A case report.

Authors:  Alpaslan Ozgun; Tolga Tuncel; Levent Emirzeoglu; Serkan Celik; Oguz Bilgi; Abdullah Haholu; Muammer Urhan; Bulent Karagoz
Journal:  Oncol Lett       Date:  2014-10-27       Impact factor: 2.967

3.  mutLBSgeneDB: mutated ligand binding site gene DataBase.

Authors:  Pora Kim; Junfei Zhao; Pinyi Lu; Zhongming Zhao
Journal:  Nucleic Acids Res       Date:  2016-10-07       Impact factor: 16.971

Review 4.  New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.

Authors:  Mourad Zerfaoui; Titilope Modupe Dokunmu; Eman Ali Toraih; Bashir M Rezk; Zakaria Y Abd Elmageed; Emad Kandil
Journal:  Cells       Date:  2021-02-10       Impact factor: 6.600

Review 5.  Is Melanoma Progression Affected by Thyroid Diseases?

Authors:  Salvatore Ulisse; Enke Baldini; Daniele Pironi; Federica Gagliardi; Domenico Tripodi; Augusto Lauro; Sabino Carbotta; Danilo Tarroni; Matteo D'Armiento; Aldo Morrone; Flavio Forte; Flaminia Frattaroli; Severino Persechino; Teresa Odorisio; Vito D'Andrea; Eleonora Lori; Salvatore Sorrenti
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.